Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8735452 | CUMBERLAND PHARMS | Treating patients with intravenous ibuprofen |
Sep, 2029
(5 years from now) | |
US9649284 | CUMBERLAND PHARMS | Treating critically ill patients with intravenous ibuprofen |
Sep, 2029
(5 years from now) | |
US9114068 | CUMBERLAND PHARMS | Treating patients with intravenous ibuprofen |
Sep, 2029
(5 years from now) | |
US8871810 | CUMBERLAND PHARMS | Treating critically ill patients with intravenous ibuprofen |
Sep, 2029
(5 years from now) | |
US9295639 | CUMBERLAND PHARMS | Treating critically ill patients with intravenous ibuprofen |
Sep, 2029
(5 years from now) | |
US9138404 | CUMBERLAND PHARMS | Treating critically ill patients with intravenous ibuprofen |
Sep, 2029
(5 years from now) | |
US9012508 | CUMBERLAND PHARMS | Administration of intravenous ibuprofen |
Sep, 2030
(6 years from now) | |
US9072661 | CUMBERLAND PHARMS | Injectable ibuprofen formulation |
Mar, 2032
(7 years from now) | |
US11806400 | CUMBERLAND PHARMS | Injectable ibuprofen formulation |
Mar, 2032
(7 years from now) | |
US9072710 | CUMBERLAND PHARMS | Injectable ibuprofen formulation |
Mar, 2032
(7 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M (M) | Nov 19, 2024 |
New Patient Population (NPP) | May 11, 2026 |
Market Authorisation Date: 11 June, 2009
Treatment: Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics, reduction in fever through anti-inflammatory, analgesic, and antipyretic activity; Manage...
Dosage: SOLUTION;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10238640 | GLAXOSMITHKLINE | Pharmaceutical suspension composition |
May, 2024
(a month from now) |
Market Authorisation Date: 27 June, 1996
Treatment: NA
Dosage: SUSPENSION;ORAL